Suzuki H , et al.. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22:1795–1803. doi: 10.1681/ASN.2011050464

• PubMed
Suzuki H , . The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22:1795–1803. doi: 10.1681/ASN.2011050464 )| false
• Search Google Scholar
• Export Citation

Rauen T , et al.. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463

• PubMed
Rauen T , . Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–2236. doi: 10.1056/NEJMoa1415463 )| false
• Search Google Scholar
• Export Citation

Lv J , et al.. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.9362

• PubMed
Lv J , . Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432–442. doi: 10.1001/jama.2017.9362 )| false
• Search Google Scholar
• Export Citation

Tumlin JA , et al.. Idiopathic IgA nephropathy: Pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol 2007; 2:1054–1061. doi: 10.2215/CJN.04351206

• PubMed
Tumlin JA , . Idiopathic IgA nephropathy: Pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol 2007; 2:1054–1061. doi: 10.2215/CJN.04351206 )| false
• Search Google Scholar
• Export Citation

Rehnberg J , et al.. Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: A Swedish population-based cohort study. J Am Soc Nephrol 2021; 32:411–423. doi: 10.1681/ASN.2020060848

• PubMed
Rehnberg J , . Inflammatory bowel disease is more common in patients with IgA nephropathy and predicts progression of ESKD: A Swedish population-based cohort study. J Am Soc Nephrol 2021; 32:411–423. doi: 10.1681/ASN.2020060848 )| false
• Search Google Scholar
• Export Citation

Cheung CK , Barratt J . Gluten and IgA nephropathy: You are what you eat?. Kidney Int 2015; 88:215–218. doi: 10.1038/ki.2015.149

• PubMed
Cheung CK , Barratt J . Gluten and IgA nephropathy: You are what you eat?. Kidney Int 2015; 88:215–218. doi: 10.1038/ki.2015.149 )| false
• Search Google Scholar
• Export Citation

Barratt J , et al.. Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999; 33:1049–1057. doi: 10.1016/S0272-6386(99)70141-1

• PubMed
Barratt J , . Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 1999; 33:1049–1057. doi: 10.1016/S0272-6386(99)70141-1 )| false
• Search Google Scholar
• Export Citation

Hiki Y , et al.. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59:1077–1085. doi: 10.1046/j.1523-1755.2001.0590031077.x

• PubMed
Hiki Y , . Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 2001; 59:1077–1085. doi: 10.1046/j.1523-1755.2001.0590031077.x )| false
• Search Google Scholar
• Export Citation

Oortwijn BD , et al.. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22:3191–3195. doi: 10.1093/ndt/gfm346

• PubMed
Oortwijn BD , . Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22:3191–3195. doi: 10.1093/ndt/gfm346 )| false
• Search Google Scholar
• Export Citation

Barratt J , et al.. Immune complex formation in IgA nephropathy: A case of the ‘right’ antibodies in the ‘wrong’ place at the ‘wrong’ time? Nephrol Dial Transplant 2009; 24:3620–3623. doi: 10.1093/ndt/gfp441

• PubMed
Barratt J , . Immune complex formation in IgA nephropathy: A case of the ‘right’ antibodies in the ‘wrong’ place at the ‘wrong’ time? Nephrol Dial Transplant 2009; 24:3620–3623. doi: 10.1093/ndt/gfp441 )| false
• Search Google Scholar
• Export Citation

McCarthy DD , et al.. Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy [published correction appears in J Clin Invest 2012; 122:778]. J Clin Invest 2011; 121:3991–4002. doi: 10.1172/JCI45563

• PubMed
McCarthy DD , . Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy [published correction appears in J Clin Invest 2012; 122:778]. J Clin Invest 2011; 121:3991–4002. doi: 10.1172/JCI45563 )| false
• Search Google Scholar
• Export Citation

Chemouny JM , et al.. Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice. Nephrol Dial Transplant 2019; 34:1135–1144. doi: 10.1093/ndt/gfy323

• PubMed
Chemouny JM , . Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice. Nephrol Dial Transplant 2019; 34:1135–1144. doi: 10.1093/ndt/gfy323 )| false
• Search Google Scholar
• Export Citation

Kiryluk K , et al.. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46:1187–1196. doi: 10.1038/ng.3118

• PubMed
Kiryluk K , . Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46:1187–1196. doi: 10.1038/ng.3118 )| false
• Search Google Scholar
• Export Citation

De Angelis M , et al.. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 2014; 9:e99006. doi: 10.1371/journal.pone.0099006

• PubMed
De Angelis M , . Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 2014; 9:e99006. doi: 10.1371/journal.pone.0099006 )| false
• Search Google Scholar
• Export Citation

Fellström BC , et al.. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017; 389:2117–2127. doi: 10.1016/S0140-6736(17)30550-0

• PubMed
Fellström BC , . Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet 2017; 389:2117–2127. doi: 10.1016/S0140-6736(17)30550-0 )| false
• Search Google Scholar
• Export Citation

Selvaskandan H , et al.. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol 2019; 23:577−588. doi: 10.1007/s10157-019-01700-1

• PubMed
Selvaskandan H , . New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol 2019; 23:577−588. doi: 10.1007/s10157-019-01700-1 )| false
• Search Google Scholar
• Export Citation